CLE Course Details

What Happens When Psychedelic-Assisted Therapy Under State Law Meets Patent Rights

Choose a state below and click "Add To Cart"
Price: $55
Course Preview
  • Description

    In May 2019, Denver decriminalized psilocybin mushrooms, beginning a far-reaching reform movement in psychedelic drugs. This wave placed pharmaceutical companies, who began to seek FDA approval of such drugs in direct opposition to activists who opposed commercialization. Oregon’s later legalization of psilocybin-assisted therapy clinics using products manufactured under state licenses only accelerated the spread and the conflict.

    This CLE course will explain the patent protections available to licensees in a state “medical psychedelic” program as well as the degree to which pharmaceutical companies who have gained FDA approval for their medicine may restrict state-licensed actors and others in the market.

  • Instructor Bio

    Noah Potter

    Noah Potter, Esq. has been practicing law as a commercial litigator in New York City since 2000. He became a drug policy reform advocate while an undergraduate political science student in 1993, and studied the evolution of the federal drug control bureaucracy. He is of counsel to the Hoban Law Group, former chair and current member of the New York City Bar Association’s Committee on Drugs and the Law, author of the New Amsterdam Psychedelic Law blog (and creator of the term “psychedelic law”), an organizer of the New York City Cannabis Parade, and a media commentator. In 2018, he assisted the Denver mushroom decriminalization campaign in selecting the language for the ballot initiative.


    Graham Pechenik

    Graham is the founder of Calyx Law, the first intellectual property law boutique to focus on cannabis and psychedelics. He is a registered patent attorney with degrees in Biochemistry and Cognitive Neuroscience. Graham founded Calyx Law in 2016, after a decade at law firms in New York and San Francisco where he obtained and defended patents on behalf of Fortune 500 companies in the agricultural, chemical, pharmaceutical, biotech, and technology industries.

    At Calyx Law, Graham has filed dozens of patents in the cannabis and psychedelics spaces, on such inventions as novel chemical compounds, pharmaceutical and nutraceutical formulations, methods of treatment, extraction processes and equipment, mechanical devices, and software. Graham also assists clients with trademarks and contracts, works on legal issues at the intersection of psychedelics with digital health and data privacy, and writes about psychedelic patents as editor-at-large of Psilocybin Alpha.